Positive News SentimentPositive NewsNASDAQ:IPSC Century Therapeutics (IPSC) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free IPSC Stock Alerts $2.98 +0.01 (+0.34%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$2.87▼$3.1450-Day Range$2.84▼$4.2752-Week Range$1.28▼$5.51Volume105,195 shsAverage Volume175,154 shsMarket Capitalization$246.89 millionP/E RatioN/ADividend YieldN/APrice Target$13.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Century Therapeutics alerts: Email Address Century Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside352.1% Upside$13.20 Price TargetShort InterestBearish8.20% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.87Based on 2 Articles This WeekInsider TradingSelling Shares$152,090 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.94) to ($1.97) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.40 out of 5 starsMedical Sector832nd out of 924 stocksBiological Products, Except Diagnostic Industry143rd out of 151 stocks 3.4 Analyst's Opinion Consensus RatingCentury Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCentury Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Century Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted8.20% of the float of Century Therapeutics has been sold short.Short Interest Ratio / Days to CoverCentury Therapeutics has a short interest ratio ("days to cover") of 12.7, which indicates bearish sentiment.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldCentury Therapeutics does not currently pay a dividend.Dividend GrowthCentury Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IPSC. Previous Next 3.3 News and Social Media Coverage News SentimentCentury Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Century Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for IPSC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Century Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $152,090.00 in company stock.Percentage Held by InsidersOnly 6.80% of the stock of Century Therapeutics is held by insiders.Percentage Held by Institutions50.20% of the stock of Century Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Century Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Century Therapeutics are expected to decrease in the coming year, from ($1.94) to ($1.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Century Therapeutics is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Century Therapeutics is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCentury Therapeutics has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Century Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 Media[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Did you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. About Century Therapeutics Stock (NASDAQ:IPSC)Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.Read More IPSC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IPSC Stock News HeadlinesMay 8, 2024 | insidertrades.comCentury Therapeutics, Inc. (NASDAQ:IPSC) Insider Sells $15,600.00 in StockJune 3 at 7:00 AM | globenewswire.comCentury Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual MeetingMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Century Therapeutics on Promising CNTY-101 Prospects and Strong Financial FootingMay 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Century Therapeutics Amid Promising Trials and Strategic AcquisitionsMay 10, 2024 | finance.yahoo.comCentury Therapeutics Inc (IPSC) Q1 2024 Earnings: Aligns with EPS Projections Amid Strategic ...May 10, 2024 | finance.yahoo.comCentury Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual MeetingMay 9, 2024 | investorplace.comIPSC Stock Earnings: Century Therapeutics Beats EPS, Misses Revenue for Q1 2024May 9, 2024 | globenewswire.comCentury Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesApril 26, 2024 | investing.comCentury Therapeutics executive sells shares worth over $15kApril 23, 2024 | finance.yahoo.comCentury Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitApril 23, 2024 | globenewswire.comCentury Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitApril 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Century Therapeutics Amidst Strong Financial Backing and Promising Clinical AdvancesApril 14, 2024 | uk.investing.comCentury Therapeutics shares target cut, retains OverweightApril 12, 2024 | msn.comCentury Therapeutics Gears Up to Conquer Highly Unmet Areas in Autoimmune Disease TreatmentsApril 12, 2024 | markets.businessinsider.comCentury Therapeutics: Hold Rating Justified Amid Strategic Acquisition and Ongoing Clinical TrialsApril 11, 2024 | globenewswire.comCentury Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade TherapeuticsApril 8, 2024 | globenewswire.comCentury Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual MeetingMarch 29, 2024 | finance.yahoo.comCentury Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash WiselyMarch 19, 2024 | markets.businessinsider.comStrong Buy Rating for Century Therapeutics Amid Promising CNTY-101 Developments and Market CatalystsMarch 19, 2024 | globenewswire.comCentury Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceMarch 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Century Therapeutics on Strong Clinical and Financial OutlookMarch 15, 2024 | finanznachrichten.deCentury Therapeutics, Inc.: Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdatesMarch 14, 2024 | investorplace.comIPSC Stock Earnings: Century Therapeutics Misses EPS, Misses Revenue for Q4 2023March 14, 2024 | benzinga.comCentury Therapeutics: Q4 Earnings InsightsMarch 14, 2024 | globenewswire.comCentury Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdatesSee More Headlines Receive IPSC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Century Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/03/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:IPSC CUSIPN/A CIK1850119 Webwww.centurytx.com Phone267-817-5790FaxN/AEmployees152Year FoundedN/APrice Target and Rating Average Stock Price Target$13.20 High Stock Price Target$24.00 Low Stock Price Target$5.00 Potential Upside/Downside+343.0%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-136,670,000.00 Net Margins-9,742.41% Pretax Margin-9,693.21% Return on Equity-59.74% Return on Assets-32.51% Debt Debt-to-Equity RatioN/A Current Ratio12.44 Quick Ratio12.44 Sales & Book Value Annual Sales$2.23 million Price / Sales110.71 Cash FlowN/A Price / Cash FlowN/A Book Value$3.06 per share Price / Book0.97Miscellaneous Outstanding Shares82,850,000Free Float77,213,000Market Cap$246.89 million OptionableOptionable Beta1.44 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Brent Pfeiffenberger M.B.A.Pharm.D., CEO & DirectorDr. Adrienne Farid Ph.D. (Age 62)COO & Head of Early Development Comp: $670.29kDr. Gregory Russotti Ph.D. (Age 57)Chief Technology & Manufacturing Officer Comp: $852.56kMr. Douglas Carr CPAInterim Principal Financial Officer, Senior VP of Finance & Operations and SecretaryMr. Kenneth J. Dow J.D.Senior VP of General CounselDr. Shane Williams Ph.D.Chief People OfficerDr. Hyam I. Levitsky M.D. (Age 66)President of Research & Development Comp: $502.12kMichael Naso Ph.D.Senior VP of Cell EngineeringDr. Nick Trede M.D.Ph.D., Senior VP & Head of Clinical DevelopmentMore ExecutivesKey CompetitorsInvivydNASDAQ:IVVDNkartaNASDAQ:NKTXKinnate BiopharmaNASDAQ:KNTEbluebird bioNASDAQ:BLUEAlloVirNASDAQ:ALVRView All CompetitorsInsiders & InstitutionsJacobs Levy Equity Management Inc.Bought 192,915 shares on 5/16/2024Ownership: 0.453%Vanguard Group Inc.Bought 14,000 shares on 5/10/2024Ownership: 1.757%Gregory RussottiSold 5,000 sharesTotal: $15,600.00 ($3.12/share)Douglas CarrSold 257 sharesTotal: $799.27 ($3.11/share)Adrienne FaridSold 913 sharesTotal: $2,839.43 ($3.11/share)View All Insider TransactionsView All Institutional Transactions IPSC Stock Analysis - Frequently Asked Questions Should I buy or sell Century Therapeutics stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Century Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IPSC shares. View IPSC analyst ratings or view top-rated stocks. What is Century Therapeutics' stock price target for 2024? 5 brokers have issued 1-year target prices for Century Therapeutics' shares. Their IPSC share price targets range from $5.00 to $24.00. On average, they predict the company's share price to reach $13.20 in the next twelve months. This suggests a possible upside of 352.1% from the stock's current price. View analysts price targets for IPSC or view top-rated stocks among Wall Street analysts. How have IPSC shares performed in 2024? Century Therapeutics' stock was trading at $3.32 at the start of the year. Since then, IPSC shares have decreased by 12.0% and is now trading at $2.92. View the best growth stocks for 2024 here. When is Century Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our IPSC earnings forecast. How were Century Therapeutics' earnings last quarter? Century Therapeutics, Inc. (NASDAQ:IPSC) announced its quarterly earnings results on Thursday, May, 9th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.05. The business had revenue of $0.86 million for the quarter, compared to the consensus estimate of $0.30 million. Century Therapeutics had a negative net margin of 9,742.41% and a negative trailing twelve-month return on equity of 59.74%. When did Century Therapeutics IPO? Century Therapeutics (IPSC) raised $201 million in an IPO on Friday, June 18th 2021. The company issued 10,600,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler served as the underwriters for the IPO. Who are Century Therapeutics' major shareholders? Century Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (1.76%), Jacobs Levy Equity Management Inc. (0.45%) and Mirae Asset Global Investments Co. Ltd. (0.02%). Insiders that own company stock include Adrienne Farid, Douglas Carr, Eli Casdin, Gregory Russotti, Luis Borges and Versant Venture Capital Vi, L. View institutional ownership trends. How do I buy shares of Century Therapeutics? Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IPSC) was last updated on 6/3/2024 by MarketBeat.com Staff From Our PartnersAlert: Your Bank is Dying – Act Now or Lose Everything!Priority GoldDoes this make you sick?Allegiance GoldNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemWeiss Ratings[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressNext President (Not Trump. Not Biden.)The Freeport SocietyHistoric Crash Could Wipe Away Your 401k (Govt Debt Explosion)Birch Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Century Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.